Joseph Thome
Stock Analyst at TD Cowen
(0.57)
# 3,805
Out of 4,784 analysts
22
Total ratings
33.33%
Success rate
-18.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $14.44 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $306.97 | +30.31% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $10.05 | - | 1 | Jul 2, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | n/a | $2.53 | - | 2 | Jun 18, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $33.21 | +2.38% | 1 | Jun 17, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $90 | $131.81 | -31.72% | 2 | Apr 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $1.99 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $1.48 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $54.24 | -44.69% | 2 | Mar 1, 2024 | |
| YMAB Y-mAbs Therapeutics | Downgrades: Market Perform | n/a | $4.81 | - | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $34.26 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.24 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.51 | - | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $118.53 | +9.68% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.07 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.56 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.23 | - | 1 | Jul 15, 2021 |
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $14.44
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $306.97
Upside: +30.31%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $10.05
Upside: -
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.53
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $33.21
Upside: +2.38%
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Buy
Price Target: $80 → $90
Current: $131.81
Upside: -31.72%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $1.99
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.48
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $54.24
Upside: -44.69%
Y-mAbs Therapeutics
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.81
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $34.26
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.24
Upside: -
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $3.51
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $118.53
Upside: +9.68%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $8.07
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.56
Upside: -
Jul 15, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.23
Upside: -